Figure 2. Relative Risk (RR) for Neurocognitive Deficits Among Survivors of Childhood Cancer With Severe Hearing Impairment (HI) vs Survivors With Normal Hearing or With Mild HI, Stratified by Treatment Exposure .

A, No exposure group (n = 740) comprised survivors who were not treated with platinum-based chemotherapy or cochlear radiotherapy (RT). B, Platinum-only exposure group (n = 307) comprised survivors who were treated with cisplatin and/or carboplatin chemotherapy. C, Cochlear RT exposure group (n = 473) comprised survivors who were treated with cochlear RT with or without platinum-based chemotherapy. Analysis was adjusted for age at diagnosis, time since diagnosis, sex, and treatment variables (if any) within the group. These variables were cranial RT dose, methotrexate chemotherapy treatment (yes or no for intrathecal and high dose), and high-dose cytarabine chemotherapy treatment (yes or no).